LADX
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q1 | -1.45 | $0 | -$553M |
| 2024 Q4 | 0.67 | $6,922 | $702M |
| 2024 Q3 | -1.67 | $0 | -$2.0B |
| 2024 Q2 | -2.59 | $0 | -$1M |
| 2024 Q1 | 0.38 | $0 | -$5,884 |
| 2023 Q4 | -1.73 | $17,752 | -$863,335 |
| 2023 Q3 | -1.65 | $0 | -$669,897 |
| 2023 Q2 | 6.45 | $0 | $3M |